Floatz logo

2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-

Acute Myeloid Leukemia, Del(5q31-Q32)

Explore 5 assets in Acute Myeloid Leukemia, Del(5q31-Q32) →
Floatz Rating
BB70/100
Confidence
Indicative
v0.2
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT00602771CT.gov
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia
—Completed———
NCT00101296CT.gov
Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
—Completed———
NCT00093418CT.gov
S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia
—Completed———
NCT00045396CT.gov
A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)
—Completed———
NCT00027872CT.gov
Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Acute Myeloid Leukemia, Del(5q31-Q32)

AssetSponsorPhaseRating
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- (this asset)National Cancer Institute (NCI)P2BB · 70
EtoposideAlice MimsP3BBB
CytarabineAlice MimsP3BBB
IdarubicinBruno C. MedeirosP2BBB
CyclophosphamideSumithira VasuP3BBB
FludarabineRutgers, The State University of New JerseyP3BBB
Cyclosporin ANational Cancer Institute (NCI)P3BBB
DaunomycinNational Cancer Institute (NCI)P3BBB
ClofarabineECOG-ACRIN Cancer Research GroupP3BB

+42 more in the Acute Myeloid Leukemia, Del(5q31-Q32) cohort

Other indications for 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-

IndicationSponsorPhaseRating
Acute Monocytic Leukemia—P2BBB · 74
Acute Megakaryoblastic Leukemia—P2BBB · 72
Acute Myeloid Leukemia With 11q23 Abnormalities—P3BBB · 72

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- in Acute Myeloid Leukemia, Del(5q31-Q32). Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/2-1h-quinolinone6-amino4-chlorophenyl1-methyl-1h-imidazol-5-ylmethyl-4-3-chlorophenyl-1-methyl-acute-myeloid-leukemia-del5q31-q32

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →